#AIEye Episode 466: GBT (OTCPINK: $GTCH) and JV Partner Alpha EDA Commence IC Design Productivity Enhancement Development, and National Grid (NYSE: $NGG) Invests in Two #AI Startups #artificialintelligence #technology

#AIEye Episode 466: GBT (OTCPINK: $GTCH) and JV Partner Alpha EDA Commence IC Design Productivity Enhancement Development, and National Grid (NYSE: $NGG) Invests in Two #AI Startups #artificialintelligence #technology

 

Global Wearable AI Market to Reach $42.34 Billion by 2026

 

Point Roberts WA, Vancouver BC – November 2, 2020  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence.

 

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/110220-AI-Eye.mp3

 

Read this in full at https://www.investorideas.com/news/2020/artificial-intelligence/11021AIEye-GBT-JV-NGG.asp

 

Hear the Ai Eye on Spotify  

 

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

 

Stocks discussed: (OTCPINK:GTCH) (NYSE:NGG)

 

GBT Technologies Inc. (OTC PINK:GTCH), along with its joint venture partner Alpha EDA, has announced that it has commenced the development of IC design productivity enhancement algorithms and methods. This technology aims to “accelerate microchips design process with a focus on advanced nodes of 7nm and below,” according to the press release. GBT’s CEO, Danny Rittman, explained:

 

"Design houses spend months and hundreds of millions of dollars to verify and tweak their designs in order to comply with the process's complex geometrical and electrical rules. Introducing advanced design rules automatic correction technology, within a wide range of arenas, will significantly shorten IC design time and therefore enable faster design and manufacturing of microchip, with higher performance and reliability. We are interested in commercializing this technology into a set of software tool's suite that will include our AI algorithms and methods. This technology will include our recent 3D IC patent implementation in order to enable the design and manufacturing of larger chips. We believe that our technology will be a game changer when it comes to an IC design productivity enhancement and will enable the design of larger and smarter chips, with higher reliability and performance."

 

National Grid Partners (NGP), the investment and innovation arm of National Grid plc (NYSE:NGG), has invested in two data analytics startups that employ artificial intelligence to protect critical infrastructure and reduce costs for customers. The two startups are: Aperio Systems, “which uses AI and machine learning (ML) to analyze and monitor industrial sensor data in real time,” and AiDash, which “uses high-resolution satellite imagery coupled with AI to help utility and energy customers transform operations and maintenance activities like vegetation management, remote monitoring and disaster management.” Lisa Lambert, the company’s Chief Technology and Innovation Officer, as well as the founder and president of NGP, said:

 

"National Grid’s ambition is to become the most intelligent transmission network in the world. We are investing in and deploying technologies across our networks to enhance resilience and reliability, while more easily integrating clean energy."

 

Global Wearable AI Market to Reach $42.34 Billion by 2026

 

A report published by Zion Market Research finds that the global Wearable AI market will grow from $10.11 billion in 2019 to $42.34 billion by the end of 2026, exhibiting a compound annual growth rate (CAGR) of 21.2 percent in the forecast period 2020-2026. An excerpt from the report summary outlines some factors driving the market:

 

Wearable Artificial intelligence device[s] will have a huge demand for the forecasted years. High demand for consumer electronic[s] from the young generation are one of the major factors promoting the growth of the market. In addition, rapid technological advancement and penetration of technology in [the] healthcare sector further boost the demand of the market. Rising sales of mobile phone[s] in countries like India and China are a major driving factor for the growth of the market. Rapid penetration of 5G technology followed by government funding will further help the market into the double digit trend.

 

Sam Mowers, Investorideas.com

 

Read and hear other editions of the AI  Eye

 

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: GTCH is a paid monthly featured company. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

#CryptoCorner Episode 471: #Bitcoin Grazes $14K Over Weekend, Hut 8 (TSX: $HUT.TO) Appoints New CEO, Paxful Launches #Crypto Visa Debit Card for US

#CryptoCorner Episode 471: #Bitcoin Grazes $14K Over Weekend, Hut 8 (TSX: $HUT.TO) Appoints New CEO, Paxful Launches #Crypto Visa Debit Card for US

 

Point Roberts, WA, Delta BC November 2, 2020 -  Investorideas.com, a leader in crypto and blockchain investing news brings you today’s edition of the Crypto Corner podcast and commentary on what’s driving cryptocurrency stocks and the crypto market.

 

Listen to today’s Crypto Corner Podcast:  

https://www.investorideas.com/Audio/Podcasts/2020/110220-CryptoMarket.mp3

 

Read this in full at https://www.investorideas.com/news/2020/crypto-corner/11021Bitcoin-HUT-Paxful.asp

 

Get the Crypto Corner Podcast on iTunes

 

Get the Crypto corner on Spotify

 

Stocks discussed: (TSX:HUT)

 

Over the weekend Bitcoin (BTC) fluctuated from briefly grazing a trading price of $14,000 on Saturday, October 31, to more or less just bubbling beneath it for the rest of that day and Sunday, according to data from CoinMarketCap. Despite failing to secure support at $14,000, Bitcoin is still up from last Monday, a week ago, when it came out of the weekend trading for around $13,200. At press time, it is trading for about $13,450.

 

Hut 8 Mining Corp. (TSX:HUT) has appointed Jaime Leverton as its CEO, replacing its current Interim CEO, Jimmy Vaiopoulos, who will return to his former role of Chief Financial Officer on December 1, 2020. Leverton, who boasts “more than 20 years of leadership in the Canadian technology industry,” according to the press release, commented:

 

“It's a privilege to join an organization on the leading edge of an industry that is building the new foundation for technological evolution. As a believer in the importance of Bitcoin in this evolution, I'm honoured to join the team as we further solidify Hut 8's place as a market leader and true technology innovator in this space."

 

Additionally, Hut 8 plans to release its third quarter 2020 financial results pre-market open on Thursday November 12, 2020.

 

The Block reports that peer-to-peer cryptocurrency marketplace Paxful has launched a crypto Visa debit card for U.S. customers. The card is the result of a collaboration with fintech startup Ternio, with the aim of giving the unbanked or underbanked access to traditional financial services. The card works by converting crypto to U.S. dollars, enabling users to make purchases or engage in banking services like opening a chequing account and making withdrawals. Paxful CEO Ray Youssef said:

 

“Whether looking to invest in education, start a business, or simply manage the financial demands of everyday life, there should be a viable option for everyone across the globe.”

 

The Cayman Islands on Saturday announced that it was developing a regulatory framework for virtual asset service providers (VASPs). The first phase of this project, which would have began on October 31, is focussing “on anti-money laundering (AML) and countering the financing of terrorism (CFT) compliance, supervision and enforcement.” The second phase will handle licensing requirements and prudential supervision, and is expected to begin in June 2021. The government’s Ministry of Financial Services believes that in taking this project on, the Cayman Islands’ “ability to regulate and attract persons and entities that deal with virtual assets as a business is now strengthened.”

 

Sam Mowers, Investorideas

 

For investors following the sector Investor Ideas has a comprehensive Bitcoin, Blockchain and Digital Currency Stocks Directory

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

 

The Crypto Corner is part of the Investor Ideas Membership content

 

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Cryptocurrency Disclaimer

Investorideas.com news content is not meant to be a solicitation to buy or sell cryptocurrencies and Investorideas.com does not directly sell cryptocurrencies; but acts as a news and research resource for interested investors following the blockchain sector.

 

Copyright and ownership: Crypto Corner is an Investorideas.com content brand

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

 

Get more Bitcoin and Blockchain Investor ideas  – news, articles, podcasts and stock directories 

#AI #Stock News: GBT (OTCPINK: $GTCH) Commenced Design Productivity Software Solutions Development; @GbtTechnologies #artificialintelligence

#AI #Stock News: GBT (OTCPINK: $GTCH) Commenced Design Productivity Software Solutions Development; @GbtTechnologies  #artificialintelligence

 

Part of its 3D Monolithic, Multi-Dimensional/Plane, Memory Structure - Integrated Circuits Allowance Commercialization

 

SAN DIEGO - November 2, 2020 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company"), announced that GBT together with Alpha EDA ("Alpha"), its joint venture partner, have developed IC design productivity enhancement algorithms and methods. This technology is aiming to accelerate microchips design process with a focus on advanced nodes of 7nm and below. The IC industry has been following Moore's law for many decades which provides that "The number of transistors on a chip becomes double approximately every two years".

 

Read this news featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2020/11021Productivity-Software.asp

 

As the demand for semiconductor products and features continues to grow, the industry demands advanced IC design technology in order to be able to provide affordable, smart chips, with low power consumption and high performance. Foundries (the factories that manufacturing the actual chips) are moving toward lower geometries (FinFET 7nm, 5nm and the upcoming 3nm) for fabricating next generation electronics. Designing microchips in lower geometries has become a major challenge. The geometrical/physical design rules of the tiny transistors are becoming a bottleneck when it comes to achieving reasonable chips design time. The physical limitations of the small node silicon device create steep challenges to handle and cause long and expensive IC design time. Another significant aspect is the time to market factor. Projects are taking much longer time due to complex design rules and process related constraints. This fact enforces Electronic Design Automation ("EDA") vendors to constantly develop new solutions and approaches for the industry's needs but they are not able to catch up with the advancements of the deep nanometer progress. As processes are moving into 7nm and below, the current physical design/verification tools do not provide sufficient performance.

 

Consequently, designs do not meet their tape-out schedules and furthermore, fail to meet functionalities and electrical rules. New approaches and methods are needed to address deep nanometer design requirements, in a reasonable time manner. Alpha has developed new systems and methods to enhance the productivity of ICs design process. In addition, GBT's existing technology is designed to enhance performance and shorten the scope of physical verification checks to quickly resolve complicated nanometer manufacturing design rules. Chips will become more power efficient, higher performance and more compact, which will have a significant impact on the silicon yield. We conservatively estimate that using Alpha developments with GBT's technologies may save between 40%-50% of an IC design cycle, eliminating design rules automatically and during early stages. These interactive technologies identify design violations during the construction of IC layout and eliminate them in real-time. In addition, Alpha's productivity solutions address electrical rules violations in order to maintain chip's power efficiency, high reliability, and high performance operation.

 

"Increasing complexity and integration, shrinking geometries and consequent physical effects have been some of the ongoing challenges of the deep nanometer era. Economy condition enforces IC design houses to move to more cost-effective design processes in order to stay in business. Reducing the size of ICs lowers power use, raises performance and reduces the cost, all important benefits at a time when companies want ever smaller devices that do more and cost less. With Alpha EDA, LLC we developed a set of algorithms and solutions that we believe will address advanced nodes" stated Danny Rittman, GBT CTO. "The ever demand of IoT technology, mobile, autonomous machines, artificial intelligence, and cyber security is growing exponentially, which acts as a driving force for scaling down transistors below the existing 7nm node for higher performance, low power and low cost. However, there are several major challenges of scaling down a transistor size, which hold IC design houses back from designing and producing better ICs, faster. These challenges are the intensive design rule compliance work and its major design time consuming. Design houses spend months and hundreds of millions of dollars to verify and tweak their designs in order to comply with the process's complex geometrical and electrical rules. Introducing advanced design rules automatic correction technology, within a wide range of arenas, will significantly shorten IC design time and therefore enable faster design and manufacturing of microchip, with higher performance and reliability. We are interested in commercializing this technology into a set of software tool's suite that will include our AI algorithms and methods. This technology will include our recent 3D IC patent implementation in order to enable the design and manufacturing of larger chips. We believe that our technology will be a game changer when it comes to an IC design productivity enhancement and will enable the design of larger and smarter chips, with higher reliability and performance" continued Dr. Rittman.

 

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) ("GBT") (http://gbtti.com) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. GBT has a portfolio of Intellectual Property that, if commercialized, is designed to include smart microchips, mobile and security applications and protocols and supporting cloud software. GBT's system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.
Media: press@gopherprotocol.com

 

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

#TherapeuticTechnology #Stock Sigyn Therapeutics (OTC: $SIGY) CEO Note: Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions; #COVID19 #CytokineStorm @Sigyn_inc

 

#TherapeuticTechnology #Stock Sigyn Therapeutics (OTC: $SIGY) CEO Note: Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions; #COVID19 #CytokineStorm @Sigyn_inc

 

SAN DIEGO, November 2, 2020 / Investorideas.com Newswire – Therapeutic technology stock news - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce.

                                            

Read this news, featuring SIGY in full at https://www.investorideas.com/news/2020/biotech/11021OTC-SIGY.asp

 

Dear Current and Candidate Shareholders,

 

We created Sigyn Therapy™ to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (The Cytokine Storm). The intent of this communication (the first in a series) is to introduce and familiarize you with our technology and therapeutic opportunities, which include large market indications that remain beyond the reach of drug therapies.

 

Cytokine storm syndrome is characterized as a dysregulated response of the immune system, which can be induced by a wide-range of infectious and non-infectious conditions. Since the outset of the current pandemic, medical journals have widely reported cytokine storm syndrome to be a leading cause of death resulting from severe COVID-19 infections.  A hallmark of the cytokine storm is an excessive or uncontrolled release of pro-inflammatory cytokines, which can induce multiple organ failure and result in death.

 

To recalibrate this dysregulated immune response, we designed Sigyn Therapy to deplete a broad-spectrum of inflammatory contributors from the bloodstream. The most prevalent condition associated with cytokine storm syndrome is sepsis.  Earlier this year, the Journal Lancet reported that sepsis kills more people around the world than all forms of cancer combined.  The Lancet reported that in 2017, there were 48.9 million cases of sepsis and 11 million deaths.  In that same year, the journal reported an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5 years old.  In the United States, sepsis was reported to be the most common cause of in-hospital deaths and accounted for more than $24 billion in annual costs.

 

To date, more than 70 controlled human studies have been conducted to evaluate the safety and benefit of candidate drugs to treat sepsis. With one brief exception (Xigris from Eli Lilly), none of these studies resulted in an approved drug therapy.  When considering the breadth of contributing inflammatory factors, sepsis is likely to remain an elusive target for therapeutic drug agents.

 

As a result of this therapeutic void, a significant opportunity for non-pharmaceutical blood purification devices has emerged. In this regard, I encourage you to learn about CytoSorbents Corporation and Toray Industries, Inc.  Both are publicly-traded organizations that we highly respect for the advancement of their respective CytoSorb and Toraymyxin devices.  Each of these industry pioneering devices are market cleared and broadly deployed to treat a wide-range of inflammatory conditions outside of the U.S.  They are being clinically evaluated in the U.S. as candidates to treat severe COVID-19 infection under FDA-awarded Emergency Use Authorizations.

 

In regards to mechanism of action, Toraymyxin has a high specificity to bind circulating endotoxin, which is reported to be a potent activator of cytokine storm syndrome. However, the Toraymyxin device does not address pro-inflammatory cytokines. Conversely, the CytoSorb device incorporates an adsorbent component that depletes pro-inflammatory cytokines from circulation, but does not address endotoxin.

 

We designed Sigyn Therapy to deplete the presence of both endotoxin and pro-inflammatory cytokines. To further optimize the potential of our therapeutic outcomes, we expanded Sigyn Therapy’s mechanism to include the elimination of larger proteins that transport cytokines and other inflammatory cargos. We refer to these as CytoVesicles.  To address this breadth of targets, we incorporate a cocktail of adsorbent components within Sigyn Therapy that each have unique binding and capture characteristics. 

 

In the medical field, the term cocktail often refers to the simultaneous administration of multiple drugs with differing mechanisms of action. However, the dosing of multiple drugs is limited by toxicity and adverse events that may result from deleterious drug interactions. Sigyn Therapy is not constrained by such limitations as our cocktail of adsorbent components are not introduced into the body.  As a result, we are able to incorporate a substantial dose of multiple adsorbents, each with differing mechanisms and capabilities to optimize the ability of Sigyn Therapy to calm the cytokine storm that underlies life-threatening inflammatory conditions.  

 

Our therapeutic opportunities include, but are not limited to sepsis, virus induced Cytokine Storm (VICS), bacteria induced Cytokine Storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. 

 

To translate our therapeutic vision into a clinical reality, we are planning a series of studies whose outcomes will be included in an Investigational Device Exemption (IDE) that we intend to submit to FDA in 2021. At present, we are conducting an in vitro study designed to validate the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines from human blood plasma. In this study, our cytokine targets include interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-a), which are each drug industry targets to treat COVID-19 infected individuals.  

 

Roche, Sanofi, Regeneron and EUSA Pharma are evaluating anti-IL-6 drugs as COVID-19 treatment candidates.  Additionally, SOBI is testing an IL-1 inhibitor and Amgen is evaluating the potential benefit of Enbrel to inhibit TNF-a in COVID-19 infected individuals.  The prospect of aligning a therapeutic drug with a specific cytokine may be limited as researchers at Stanford and Yale have reported that cytokine profiles in those suffering from severe COVID-19 infection to be consistent with those previously observed in sepsis patients.  We believe that a device with much broader capabilities will be required.

 

I look forward to keeping you updated on our endeavors to advance Sigyn Therapy.

 

Sincerely,

 

Jim Joyce 

Chairman and CEO 

Sigyn Therapeutics, Inc.

 

About Sigyn Therapeutics

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Sigyn related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in the previous Reign Resources Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jimjoyce@elevatescience.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), is a paid for service  on Investorideas.com . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our  Biotech Stocks Directory

    Get News Alerts on Biotech Stocks